Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 133.75B |
| Revenue (ttm) | 29.73B |
| Net Income (ttm) | 5.64B |
| Shares Out | n/a |
| EPS (ttm) | 10.41 |
| PE Ratio | 23.73 |
| Forward PE | 14.17 |
| Dividend | 8.59 (3.47%) |
| Ex-Dividend Date | Aug 22, 2025 |
| Volume | 640 |
| Average Volume | 283 |
| Open | 247.75 |
| Previous Close | 247.65 |
| Day's Range | 247.75 - 250.25 |
| 52-Week Range | 230.75 - 308.50 |
| Beta | 0.48 |
| RSI | 43.96 |
| Earnings Date | Aug 4, 2025 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding C...
SA analyst upgrades/downgrades: COHR, AMGN, KKR, SOFI
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow...
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Inc. (NASDAQ: AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug ...
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Inc. AMGN shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.
Planet Fitness Pumps Up FY25 Sales Guide To $1.43 Billion After Smashing Q2 Results
Planet Fitness, Inc. (NYSE: PLNT) shares traded lower on Wednesday after the company reported second-quarter adjusted earnings per share of 86 cents, beating the analyst consensus of 79 cents. Quarte...
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Three major pharmaceutical companies — Amgen Inc. (NASDAQ: AMGN), Eli Lilly and Co (NYSE: LLY), and UCB SA (OTC: UCBJY) (OTC: UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) R...
Why I Still Don't Think Amgen Is A Buy
Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline
Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share. Latest Ratings for ... Full story available on Benzinga.com
Amgen in charts: Key drug sales drop in Q2, but Otezla sees continued growth
Amgen Inc. 2025 Q2 - Results - Earnings Call Presentation
Amgen outlines $35B–$36B 2025 revenue target as volume growth offsets pricing pressure
Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript
Amgen (AMGN) Q2 Profit Jumps 21%
Stocks to Watch Afterhours: AMD, Amgen, Snap
Amgen beat Q2 revenue and profit, stock trades flat
Amgen Posts Higher Profit, Revenue On Sales Growth Among Products
Amgen beats on Q2 revenue, slightly raises guidance
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Amgen's Q2 earnings results.
Amgen beats on Q2 revenue, slightly raises guidance
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Amgen's Q2 earnings results.
Amgen quarterly results beat Wall Street estimates
Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses.
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Aug. 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025.
Will Amgen, Already Above Its 50-Day Line, Break Out On This Earnings News?
Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock, already above its 50-day line, into a breakout.
3 Dividend Stocks for August 2025
These three dividend payers have an average yield of 4.5%.